Skip to main content

Articles

Page 9 of 39

  1. TP53 is a critical tumor-suppressor gene that is mutated in more than half of all human cancers. Mutations in TP53 not only impair its antitumor activity, but also confer mutant p53 protein oncogenic properties. ...

    Authors: Jiahao Hu, Jiasheng Cao, Win Topatana, Sarun Juengpanich, Shijie Li, Bin Zhang, Jiliang Shen, Liuxin Cai, Xiujun Cai and Mingyu Chen
    Citation: Journal of Hematology & Oncology 2021 14:157
    Content type: Review Published on:

  2. Immunotherapies such as immune checkpoint blockade (ICB) and adoptive cell therapy (ACT) have revolutionized cancer treatment, especially in patients whose disease was otherwise considered incurable. However, ...

    Authors: Shaoming Zhu, Tian Zhang, Lei Zheng, Hongtao Liu, Wenru Song, Delong Liu, Zihai Li and Chong-xian Pan
    Citation: Journal of Hematology & Oncology 2021 14:156
    Content type: Review Published on:

  3. Acute myeloid leukaemia (AML) stem cells (LSCs) cause disease relapse. The CD47 “don’t eat me signal” is upregulated on LSCs and contributes to immune evasion by inhibiting phagocytosis through interacting wit...

    Authors: Siret Tahk, Binje Vick, Björn Hiller, Saskia Schmitt, Anetta Marcinek, Enrico D. Perini, Alexandra Leutbecher, Christian Augsberger, Anna Reischer, Benjamin Tast, Andreas Humpe, Irmela Jeremias, Marion Subklewe, Nadja C. Fenn and Karl-Peter Hopfner
    Citation: Journal of Hematology & Oncology 2021 14:155
    Content type: Research Published on:

  4. Liver cancer remains the leading cause of cancer death globally, and the treatment strategies are distinct for each type of malignant hepatic tumors. However, the differential diagnosis before surgery is chall...

    Authors: Ruitian Gao, Shuai Zhao, Kedeerya Aishanjiang, Hao Cai, Ting Wei, Yichi Zhang, Zhikun Liu, Jie Zhou, Bing Han, Jian Wang, Han Ding, Yingbin Liu, Xiao Xu, Zhangsheng Yu and Jinyang Gu
    Citation: Journal of Hematology & Oncology 2021 14:154
    Content type: Letter to the Editor Published on:

  5. The 3-hydroxyanthranilic acid (3-HAA), a derivative of kynurenine, was reported to suppress tumor growth. However, the function of 3-HAA largely remains unclear. Here, we report that 3-hydroxyanthranilic acid ...

    Authors: Zhaopeng Shi, Guifang Gan, Xiang Xu, Jieying Zhang, Yuan Yuan, Bo Bi, Xianfu Gao, Pengfei Xu, Wenbin Zeng, Jixi Li, Youqiong Ye, Aiwu Zhou, Naixia Zhang, Wen Liu, Shuhai Lin and Jun Mi
    Citation: Journal of Hematology & Oncology 2021 14:153
    Content type: Letter to the Editor Published on:

  6. Chimeric antigen receptor T-cell (CAR-T) therapy has shown tremendous success in eradicating hematologic malignancies. However, this success has not yet been extrapolated to solid tumors due to the limited inf...

    Authors: Feng Ji, Fan Zhang, Miaomiao Zhang, Kaili Long, Mingyue Xia, Fei Lu, Enjie Li, Jiannan Chen, Jun Li, Zhengliang Chen, Li Jing, Shaochang Jia, Rong Yang, Zhigang Hu and Zhigang Guo
    Citation: Journal of Hematology & Oncology 2021 14:152
    Content type: Letter to the Editor Published on:

  7. New approaches to stratify multiple myeloma patients based on prognosis and therapeutic decision-making, or prediction, are needed since patients are currently managed in a similar manner regardless of individ...

    Authors: Craig T. Wallington-Beddoe and Rachel L. Mynott
    Citation: Journal of Hematology & Oncology 2021 14:151
    Content type: Review Published on:

  8. Authors: Chunmeng Wang, Fengxia Shi, Yang Liu, Yajing Zhang, Liang Dong, Xiang Li, Chuan Tong, Yao Wang, Liping Su, Jing Nie and Weidong Han
    Citation: Journal of Hematology & Oncology 2021 14:150
    Content type: Correction Published on:

    The original article was published in Journal of Hematology & Oncology 2021 14:106

  9. CD19 chimeric antigen receptor (CAR)-T cells have been used to treat patients with refractory chronic lymphocytic leukemia (CLL). However, approximately 50% of patients do not respond to this therapy. To impro...

    Authors: Guoling Wang, Xiaolei Sun, Shiyu Zuo, Chuo Li, Qing Niu, Yonghui Xia, Yuan Meng, Min Liu, Zihao Fang, Xi Yang, Yanyu Jiang, Sheng Wang, Haidong Cui, Huifang Huang, Erlie Jiang, Dongming Zhou…
    Citation: Journal of Hematology & Oncology 2021 14:149
    Content type: Letter to the Editor Published on:

  10. Little is known about endogenous inhibitors of angiogenic growth factors. In this study, we identified a novel endogenous anti-angiogenic factor expressed in pericytes and clarified its underlying mechanism an...

    Authors: Jin-Woo Lee, Jin Hur, Yoo-Wook Kwon, Cheong-Whan Chae, Jae-Il Choi, Injoo Hwang, Ji-Yeon Yun, Jin-A Kang, Young-Eun Choi, Young Hyun Kim, Sang Eun Lee, Cheol Lee, Dong Hyun Jo, Heeyoung Seok, Byong Seung Cho, Sung Hee Baek…
    Citation: Journal of Hematology & Oncology 2021 14:148
    Content type: Research Published on:

  11. Immune checkpoint therapy has achieved significant efficacy by blocking inhibitory pathways to release the function of T lymphocytes. In the clinic, anti-programmed cell death protein 1/programmed cell death l...

    Authors: Wenjing Qian, Mingfang Zhao, Ruoyu Wang and Heming Li
    Citation: Journal of Hematology & Oncology 2021 14:147
    Content type: Review Published on:

  12. Our previous work showed that the anti-TGF-β/PD-L1 bispecific antibody YM101 effectively overcame anti-PD-L1 resistance in immune-excluded tumor models. However, in immune-desert models, the efficacy of YM101 ...

    Authors: Ming Yi, Mengke Niu, Jing Zhang, Shiyu Li, Shuangli Zhu, Yongxiang Yan, Ning Li, Pengfei Zhou, Qian Chu and Kongming Wu
    Citation: Journal of Hematology & Oncology 2021 14:146
    Content type: Research Published on:

  13. The consensus recommendations in 2018 from The Chinese Society of Hematology (CSH) on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation (allo-HSCT) f...

    Authors: Xiao-hui Zhang, Jing Chen, Ming-Zhe Han, He Huang, Er-lie Jiang, Ming Jiang, Yong-rong Lai, Dai-hong Liu, Qi-Fa Liu, Ting Liu, Han-yun Ren, Yong-Ping Song, Zi-min Sun, Xiao-wen Tang, Jian-min Wang, De-pei Wu…
    Citation: Journal of Hematology & Oncology 2021 14:145
    Content type: Review Published on:

  15. Malignant adenomyoepithelioma (AME) of the breast is an exceptionally rare form of breast cancer, with a significant metastatic potential. Chemotherapy has been used in the management of advanced AME patients,...

    Authors: Ivan Bièche, Florence Coussy, Rania El-Botty, Sophie Vacher, Sophie Château-Joubert, Ahmed Dahmani, Elodie Montaudon, Cécile Reyes, David Gentien, Fabien Reyal, Francesco Ricci, André Nicolas, Caterina Marchio, Anne Vincent-Salomon, Marick Laé and Elisabetta Marangoni
    Citation: Journal of Hematology & Oncology 2021 14:143
    Content type: Letter to the Editor Published on:

  16. Tumor microenvironment (TME) is a dynamic cellular milieu to promote tumor angiogenesis, growth, proliferation, and metastasis, while derailing the host anti-tumor response. TME impedes bispecific antibody (Bs...

    Authors: Jeong A. Park, Linlin Wang and Nai-Kong V. Cheung
    Citation: Journal of Hematology & Oncology 2021 14:142
    Content type: Research Published on:

  17. Pancreatic cancer has the worst prognosis among common tumors which is attributed to its aggressive phenotype, diagnosis at advanced, inoperable stages, and resistance to systemic therapy. Non-coding RNAs (ncR...

    Authors: Moritz Reese and Sameer A. Dhayat
    Citation: Journal of Hematology & Oncology 2021 14:141
    Content type: Review Published on:

  18. In the absence of randomized studies directly comparing chimeric antigen receptor T cell therapies, this study used matching-adjusted indirect comparisons (MAIC) to evaluate the comparative efficacy and safety...

    Authors: David G. Maloney, John Kuruvilla, Fei Fei Liu, Ana Kostic, Yeonhee Kim, Ashley Bonner, Yixie Zhang, Christopher P. Fox and Guillaume Cartron
    Citation: Journal of Hematology & Oncology 2021 14:140
    Content type: Research Published on:

  19. The pathogenesis of chronic myeloid leukemia (CML) is the formation of the BCR/ABL protein, which is encoded by the bcr/abl fusion gene, possessing abnormal tyrosine kinase activity. Despite the wide applicati...

    Authors: Guoyun Jiang, Zhenglan Huang, Ying Yuan, Kun Tao and Wenli Feng
    Citation: Journal of Hematology & Oncology 2021 14:139
    Content type: Research Published on:

  20. Targeting pathogenic proteins with small-molecule inhibitors (SMIs) has become a widely used strategy for treating malignant tumors. However, most intracellular proteins have been proven to be undruggable due ...

    Authors: Haobin Li, Jinyun Dong, Maohua Cai, Zhiyuan Xu, Xiang-Dong Cheng and Jiang-Jiang Qin
    Citation: Journal of Hematology & Oncology 2021 14:138
    Content type: Review Published on:

  21. Quantification of measurable residual disease (MRD) provides critical prognostic information in acute myeloid leukemia (AML). A variety of platforms exist for MRD detection, varying in their sensitivity and ap...

    Authors: Marisa J. L. Aitken, Farhad Ravandi, Keyur P. Patel and Nicholas J. Short
    Citation: Journal of Hematology & Oncology 2021 14:137
    Content type: Review Published on:

  22. Extracellular vesicles (EVs) are cell-derived membrane structures enclosing proteins, lipids, RNAs, metabolites, growth factors, and cytokines. EVs have emerged as essential intercellular communication regulat...

    Authors: Zhijie Weng, Bowen Zhang, Chenzhou Wu, Fanyuan Yu, Bo Han, Bo Li and Longjiang Li
    Citation: Journal of Hematology & Oncology 2021 14:136
    Content type: Review Published on:

  25. Most older patients with acute myeloid leukemia (AML) who attain morphologic remission with intensive chemotherapy (IC) will eventually relapse and post-relapse prognosis is dismal. In the pivotal QUAZAR AML-0...

    Authors: Farhad Ravandi, Gail J. Roboz, Andrew H. Wei, Hartmut Döhner, Christopher Pocock, Dominik Selleslag, Pau Montesinos, Hamid Sayar, Maurizio Musso, Angela Figuera-Alvarez, Hana Safah, William Tse, Sang Kyun Sohn, Devendra Hiwase, Timothy Chevassut, Francesca Pierdomenico…
    Citation: Journal of Hematology & Oncology 2021 14:133
    Content type: Research Published on:

  26. Mantle cell lymphoma (MCL) is a rare, aggressive and incurable subtype of non-Hodgkin’s B-cell lymphoma. The principal barrier is frequent clinical relapse to multiple lines of therapies, including new FDA-app...

    Authors: Vivian Changying Jiang, Yang Liu, Alexa Jordan, Joseph McIntosh, Yijing Li, Yuxuan Che, Katti A. Jessen, Brian J. Lannutti and Michael Wang
    Citation: Journal of Hematology & Oncology 2021 14:132
    Content type: Letter to the Editor Published on:

  27. Clinical features and outcomes of FL patients in Chinese population are limited, thus promoting us to perform this analysis on a large cohort of 1845 patients with FL enrolled from nine medical centers nationw...

    Authors: Jie Zha, Liyuan Fan, Shuhua Yi, Haifeng Yu, Zhong Zheng, Wei Xu, Manman Deng, Zhijuan Lin, Zhifeng Li, Lingyan Ping, Xiaohua He, Feili Chen, Ying Xie, Biyun Chen, Huilai Zhang, Li Wang…
    Citation: Journal of Hematology & Oncology 2021 14:131
    Content type: Letter to the Editor Published on:

  28. YY-20394, an oral phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor, was investigated in a first-in-human study of patients with relapsed or refractory B-cell malignancies. During dose escalation, 25 patie...

    Authors: Bo Jiang, Junyuan Qi, Yuqin Song, Zengjun Li, Meifeng Tu, Lingyan Ping, Zongliang Liu, Hanying Bao, Zusheng Xu and Lugui Qiu
    Citation: Journal of Hematology & Oncology 2021 14:130
    Content type: Letter to the Editor Published on:

  29. METex14 skipping mutations occur in about 3–4% of lung adenocarcinoma patients and 1–2% of patients with other lung cancer histology. The MET receptor tyrosine kinase and its ligand hepatocyte growth factor (H...

    Authors: Leylah M. Drusbosky, Richa Dawar, Estelamari Rodriguez and Chukwuemeka V. Ikpeazu
    Citation: Journal of Hematology & Oncology 2021 14:129
    Content type: Review Published on:

  30. Biomarkers-guided precision therapeutics has revolutionized the clinical development and administration of molecular-targeted anticancer agents. Tailored precision cancer therapy exhibits better response rate ...

    Authors: Hui Hua, Hongying Zhang, Jingzhu Chen, Jiao Wang, Jieya Liu and Yangfu Jiang
    Citation: Journal of Hematology & Oncology 2021 14:128
    Content type: Review Published on:

  31. The PI3K/AKT/mTOR (PAM) pathway is a key regulator of tumor therapy resistance. We investigated M2698, an oral p70S6K/AKT dual inhibitor, in patients with advanced cancer who failed standard therapies.

    Authors: Apostolia-Maria Tsimberidou, Jamie V. Shaw, Dejan Juric, Claire Verschraegen, Amy M. Weise, John Sarantopoulos, Gilberto Lopes, John Nemunaitis, Monica Mita, Haeseong Park, Barbara Ellers-Lenz, Hui Tian, Wenyuan Xiong, Remigiusz Kaleta and Razelle Kurzrock
    Citation: Journal of Hematology & Oncology 2021 14:127
    Content type: Research Published on:

  32. The assessment of measurable residual disease (MRD) in bone marrow has proven of prognostic relevance in patients with multiple myeloma (MM). Nevertheless, and unlike other hematologic malignancies, the use of...

    Authors: Joaquin Martinez-Lopez, Rafael Alonso, Sandy W. Wong, Rafael Rios, Nina Shah, Yanira Ruiz-Heredia, Jose Maria Sanchez-Pina, Ricardo Sanchez, Natasha Bahri, Irene Zamanillo, Maria Poza, Natalia Buenache, Cristina Encinas, Luis Juarez, Fatima Miras, Luis Collado…
    Citation: Journal of Hematology & Oncology 2021 14:126
    Content type: Letter to the Editor Published on:

  34. The bispecific antibody (bsAbs) research around the world has undergone great changes. We analyzed the global trend of bsAbs research and compared the differences in clinical research of bsAbs between China an...

    Authors: Zhonghan Zhang, Fan Luo, Jiaxin Cao, Feiteng Lu, Yang Zhang, Yuxiang Ma, Kangmei Zeng, Li Zhang and Hongyun Zhao
    Citation: Journal of Hematology & Oncology 2021 14:124
    Content type: Letter to the Editor Published on:

  35. Thromboembolism is a frequent cause of severity and mortality in COVID-19. However, the etiology of this phenomenon is not well understood. A cohort of 1186 subjects, from the GEN-COVID consortium, infected by...

    Authors: Chiara Fallerini, Sergio Daga, Elisa Benetti, Nicola Picchiotti, Kristina Zguro, Francesca Catapano, Virginia Baroni, Simone Lanini, Alessandro Bucalossi, Giuseppe Marotta, Francesca Colombo, Margherita Baldassarri, Francesca Fava, Giada Beligni, Laura Di Sarno, Diana Alaverdian…
    Citation: Journal of Hematology & Oncology 2021 14:123
    Content type: Letter to the Editor Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2023 16:11

  36. During acute myeloid leukemia (AML) growth, the bone marrow (BM) niche acquires significant vascular changes that can be offset by therapeutic blast cytoreduction. The molecular mechanisms of this vascular pla...

    Authors: Bin Zhang, Le Xuan Truong Nguyen, Dandan Zhao, David E. Frankhouser, Huafeng Wang, Dinh Hoa Hoang, Junjing Qiao, Christina Abundis, Matthew Brehove, Yu-Lin Su, Yuxin Feng, Anthony Stein, Lucy Ghoda, Adrianne Dorrance, Danilo Perrotti, Zhen Chen…
    Citation: Journal of Hematology & Oncology 2021 14:122
    Content type: Research Published on:

  37. MYC oncogene is a transcription factor with a wide array of functions affecting cellular activities such as cell cycle, apoptosis, DNA damage response, and hematopoiesis. Due to the multi-functionality of MYC,...

    Authors: Seyed Esmaeil Ahmadi, Samira Rahimi, Bahman Zarandi, Rouzbeh Chegeni and Majid Safa
    Citation: Journal of Hematology & Oncology 2021 14:121
    Content type: Review Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2021 14:135

  38. Pancreatic cancer’s poor prognosis is caused by distal metastasis, which is associated with epigenetic changes. However, the role of the 3D epigenome in pancreatic cancer biology, especially its metastasis, re...

    Authors: Bo Ren, Jinshou Yang, Chengcheng Wang, Gang Yang, Huanyu Wang, Yuan Chen, Ruiyuan Xu, Xuning Fan, Lei You, Taiping Zhang and Yupei Zhao
    Citation: Journal of Hematology & Oncology 2021 14:120
    Content type: Research Published on:

  39. In a population of 42 Philadelphia negative myeloproliferative neoplasm patients, all on systemic active treatment, the likelihood of responding to anti-SARS-CoV-2 BNT162b2 vaccine at 2 weeks after the second ...

    Authors: Fulvia Pimpinelli, Francesco Marchesi, Giulia Piaggio, Diana Giannarelli, Elena Papa, Paolo Falcucci, Antonio Spadea, Martina Pontone, Simona Di Martino, Valentina Laquintana, Antonia La Malfa, Enea Gino Di Domenico, Ornella Di Bella, Gianluca Falzone, Fabrizio Ensoli, Branka Vujovic…
    Citation: Journal of Hematology & Oncology 2021 14:119
    Content type: Letter to the Editor Published on:

  40. Although chimeric antigen receptor (CAR)-engineered T cells have shown great success in the treatment of B cell malignancies, this strategy has limited efficacy in patients with solid tumors. In mouse CAR-T ce...

    Authors: Nengzhi Pang, Jingxuan Shi, Le Qin, Aiming Chen, Yuou Tang, Hainan Yang, Yufeng Huang, Qingde Wu, Xufeng Li, Bingjia He, Tianheng Li, Baoxia Liang, Jinglin Zhang, Bihui Cao, Manting Liu, Yunfei Feng…
    Citation: Journal of Hematology & Oncology 2021 14:118
    Content type: Letter to the Editor Published on:

  41. N6-methyladenosine (m6A) has emerged as an abundant modification throughout the transcriptome with widespread functions in protein-coding and noncoding RNAs. It affects the fates of modified RNAs, including th...

    Authors: Wei Huang, Tian-Qi Chen, Ke Fang, Zhan-Cheng Zeng, Hua Ye and Yue-Qin Chen
    Citation: Journal of Hematology & Oncology 2021 14:117
    Content type: Review Published on:

  42. RAS mutations (HRAS, NRAS, and KRAS) are among the most common oncogenes, and around 19% of patients with cancer harbor RAS mutations. Cells harboring RAS mutations tend to undergo malignant transformation and ex...

    Authors: Kun Chen, Yalei Zhang, Ling Qian and Peng Wang
    Citation: Journal of Hematology & Oncology 2021 14:116
    Content type: Review Published on:

  44. Metabolic rewiring offers novel therapeutic opportunities in cancer. Until recently, there was scant information regarding soft tissue sarcomas, due to their heterogeneous tissue origin, histological definitio...

    Authors: Richard Miallot, Franck Galland, Virginie Millet, Jean-Yves Blay and Philippe Naquet
    Citation: Journal of Hematology & Oncology 2021 14:114
    Content type: Review Published on:

  45. Relapses of CD19-expressing leukemia in patients who achieved initial remission after CART cell treatment have been reported to correlate with poor CART cells persistence. Sustained tonic signaling or strong a...

    Authors: Hao Zhang, Yongxian Hu, Mi Shao, Xinyi Teng, Penglei Jiang, Xiujian Wang, Hui Wang, Jiazhen Cui, Jian Yu, Zuyu Liang, Lijuan Ding, Yingli Han, Jieping Wei, Yulin Xu, Xiaoqing Li, Wei Shan…
    Citation: Journal of Hematology & Oncology 2021 14:113
    Content type: Letter to the Editor Published on:

  46. Long non-coding RNAs (lncRNAs) are important epigenetic regulators, which play critical roles in diverse physiological and pathological processes. However, the regulatory mechanism of lncRNAs in lung carcinoge...

    Authors: Xinyi Qian, Juze Yang, Qiongzi Qiu, Xufan Li, Chengxi Jiang, Jia Li, Liangliang Dong, Kejing Ying, Bingjian Lu, Enguo Chen, Pengyuan Liu and Yan Lu
    Citation: Journal of Hematology & Oncology 2021 14:112
    Content type: Research Published on:

  47. Patients with RR DLBCL who have received ≥ 2 lines of therapy have limited treatment options and an expected overall survival (OS) of < 6 months. The SADAL study evaluated single-agent oral selinexor in patien...

    Authors: Marie Maerevoet, Josee M. Zijlstra, George Follows, Rene-Olivier Casasnovas, J. S. P. Vermaat, Nagesh Kalakonda, Andre Goy, Sylvain Choquet, Eric Van Den Neste, Brian Hill, Catherine Thieblemont, Federica Cavallo, Fatima De la Cruz, John Kuruvilla, Nada Hamad, Ulrich Jaeger…
    Citation: Journal of Hematology & Oncology 2021 14:111
    Content type: Letter to the Editor Published on:

  48. CPX-351 (United States: Vyxeos®; Europe: Vyxeos® Liposomal), a dual-drug liposomal encapsulation of daunorubicin and cytarabine in a synergistic 1:5 molar ratio, is approved by the US FDA and the EMA for the trea...

    Authors: Jorge E. Cortes, Tara L. Lin, Geoffrey L. Uy, Robert J. Ryan, Stefan Faderl and Jeffrey E. Lancet
    Citation: Journal of Hematology & Oncology 2021 14:110
    Content type: Research Published on:

  49. The prognosis for diffuse gliomas is very poor and the mechanism underlying their malignant progression remains unclear. Here, we aimed to elucidate the role and mechanism of the RNA N6,2′-O-dimethyladenosine (m6

    Authors: Rui-Chao Chai, Yu-Zhou Chang, Xin Chang, Bo Pang, Song Yuan An, Ke-Nan Zhang, Yuan-Hao Chang, Tao Jiang and Yong-Zhi Wang
    Citation: Journal of Hematology & Oncology 2021 14:109
    Content type: Research Published on:
JHO logo
Submit manuscript

Follow

Annual Journal Metrics

  • 2022 Citation Impact
    28.5 - 2-year Impact Factor
    23.1 - 5-year Impact Factor
    4.045 - SNIP (Source Normalized Impact per Paper)
    6.046 - SJR (SCImago Journal Rank)

    2023 Speed
    5 days submission to first editorial decision for all manuscripts (Median)
    59 days submission to accept (Median)

    2023 Usage 
    3,173,795 downloads
    2,671 Altmetric mentions

On the blog

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here. 

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us